Literature DB >> 3912958

Long-term immunosuppressive treatment in Crohn's disease.

M Nyman, I Hansson, S Eriksson.   

Abstract

We studied the clinical effects of long-term immunosuppressive treatment in 42 patients with severe Crohn's disease and extensive colonic involvement. Mean observation period before and after start of therapy exceeded 5 years. All but one of the patients receiving azathioprine or 6-mercaptopurine improved, and 11 of 42 attained complete remission during therapy. Cyclophosphamide was substituted for azathioprine with inferior results in four patients with pancreatitis soon after initiation of azathioprine therapy. The frequency of both local and systemic complications decreased significantly during the period of therapy. Prednisolone could be withdrawn in 25 patients and reduced to less than 7.5 mg every other day in the others. The average remission period after withdrawal of all drugs in 10 patients was 40 months. The results were superior to those in a surgical series with comparable observation time drawn from the same background population. Aside from pancreatitis in four patients, no serious side effects were seen. Fertility was unaffected. The data demonstrate the feasibility of long-term azathioprine (6-mercaptopurine) treatment in extensive Crohn's disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3912958     DOI: 10.3109/00365528509089276

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  10 in total

Review 1.  Medical or surgical treatment for Crohn's disease?

Authors:  R N Allan
Journal:  Postgrad Med J       Date:  1988-10       Impact factor: 2.401

Review 2.  Surgical treatment of inflammatory bowel disease--a review of some current opinions and controversies.

Authors:  G Ekelund; T Lindhagen; C Lindström; J Stewénius
Journal:  Jpn J Surg       Date:  1987-11

Review 3.  Medical treatment of inflammatory bowel disease: new therapies, new drugs.

Authors:  L R Sutherland
Journal:  CMAJ       Date:  1987-11-01       Impact factor: 8.262

4.  Low-dose oral methotrexate in refractory inflammatory bowel disease.

Authors:  T H Baron; C D Truss; C O Elson
Journal:  Dig Dis Sci       Date:  1993-10       Impact factor: 3.199

5.  Withdrawal of long-term maintenance treatment with azathioprine tends to increase relapse risk in patients with Crohn's disease.

Authors:  Heimo H Wenzl; Christian Primas; Gottfried Novacek; Alexander Teml; Anna Öfferlbauer-Ernst; Christoph Högenauer; Harald Vogelsang; Wolfgang Petritsch; Walter Reinisch
Journal:  Dig Dis Sci       Date:  2014-11-08       Impact factor: 3.199

6.  Safety and efficacy of intravenous pulse cyclophosphamide in acute steroid refractory inflammatory bowel disease.

Authors:  A Stallmach; B M Wittig; C Moser; J Fischinger; R Duchmann; M Zeitz
Journal:  Gut       Date:  2003-03       Impact factor: 23.059

Review 7.  Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease.

Authors:  Nilesh Chande; Cassandra M Townsend; Claire E Parker; John K MacDonald
Journal:  Cochrane Database Syst Rev       Date:  2016-10-26

Review 8.  Inflammatory bowel disease.

Authors:  G M Van Rosendaal
Journal:  CMAJ       Date:  1989-07-15       Impact factor: 8.262

Review 9.  Relapse rate following azathioprine withdrawal in maintaining remission for Crohn's disease: a meta-analysis.

Authors:  Helen French; A Mark Dalzell; Ramesh Srinivasan; Wael El-Matary
Journal:  Dig Dis Sci       Date:  2011-04-08       Impact factor: 3.199

10.  Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience.

Authors:  W R Connell; M A Kamm; J K Ritchie; J E Lennard-Jones
Journal:  Gut       Date:  1993-08       Impact factor: 23.059

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.